Intraocular delivery compositions and methods

• US 20030185892A1
• Filed: 11/27/2002
• Published: 10/02/2003
• Est. Priority Date: 08/17/2001
• Status: Abandoned Application

• Current Assignee: BioSante Pharmaceuticals, Inc.
• Original Assignee: BioSante Pharmaceuticals, Inc.
• Inventors: He, Qing, Bell, Steve J. D., Potter, David E., Chu, Teh-Ching
• Application Number:
  US10/306,062
• Publication Number:
  US 20030185892A1
• Time in Patent Office: Days
• US Class Current: 424/489
• CPC Class Codes: A61K 9/0034 Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
• CPC Class Codes: A61K 9/0043 Nose
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61K 9/1611 Inorganic compounds
• CPC Class Codes: A61K 9/1676 having a drug-free core with discrete complete coating layer containing drug adsorbates of liquid drug formulations on inert powders without simultaneous granulation step A61K9/141; with further drug-free outer coating A61K9/5078; drug conjugated to non-active particles A61K47/6921
• CPC Class Codes: A61K 9/51 Nanocapsules; Nanoparticles; nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00
• CPC Class Codes: A61K 9/5115 Inorganic compounds
• CPC Class Codes: A61K 9/5161 Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
• CPC Class Codes: A61K 9/5192 Processes

Abstract

The present invention relates to intraocular drug delivery for treating ocular diseases. Particularly, the invention relates to particles useful for the delivery of certain pharmacologically active agents to treat ocular diseases. The particles contain calcium phosphate core particles, particularly nanoparticles, as delivery agents and adjuvants. The invention also relates to methods of making such particles and to methods of treating ocular disease by delivery of a therapeutic drug to an ocular surface using the particles of this invention. The invention further relates to methods of regulating ocular pressure using certain formulations according to the present invention.

Claims

1. A particle comprising calcium phosphate and a pharmacologically active agent at least partially coating the particle or impregnating the particle or both, wherein the particle is adapted to deliver the pharmacologically active agent to an ocular surface of a patient in need thereof for treatment of an ocular disease.

2. The particle of claim 1, further comprising a surface modifying agent, such as polyethylene glycol.

3. The particle of claim 1, further comprising a surface modifying agent, such as polyethylene glycol, wherein the pharmacologically active agent is located on the surface of the particle, impregnated in the particle, or both.

4. The particle of claim 1, wherein the pharmacologically active agent is a therapeutic drug used to treat glaucoma, uveitis, retinitis pigmentosa, macular degeneration, retinopathy, retinal vascular diseases, and other vascular anomalies, endophthalmitis, infectious diseases, inflammatory but non-infectious diseases, ocular ischemia syndrome, peripheral retinal degenerations, retinal degenerations, choroidal disorders and tumors, vitreous disorders, and inflammatory optic neuropathies.

5. The particle of claim 1, wherein the pharmacologically active agent is an antibiotic, an antimicrobial agent, a therapeutic monoclonal antibody, such as tetracycline hydrochloride, leucomycin, penicillin, penicillin derivatives, erythromycin, sulphathiazole and nitrofurazone;

a local anesthetic such as benzocaine;

a vasoconstrictor such as phenylephrine hydrochloride, tetrahydrozoline hydrochloride, naphazoline nitrate, oxymetazoline hydrochloride and tramazoline hydrochloride;

a cardiotonic such as digitalis and digoxin;

a vasodilator such as nitro-glycerine and papaverine hydrochloride;

an antiseptic such as chlorhexidine hydrochloride, hexylresorcinol, dequaliniumchloride and ethacridine;

an enzyme such as lysozyme chloride and dextranase;

sex hormones;

hypotensives;

sedatives;

anti-tumor agents;

steroidal anti-inflammatory agents such as hydro-cortisone, prednisone, fluticasone, prednisolone, triamcinolone, triamcinolone acetonide, dexamethasone, betamethasone, beclomethasone, and beclomethasone dipropionate;

non-steroidal anti-inflammatory agents such as acetaminophen, aspirin, aminopyrine, phenylbutazone, mefanamic acid, ibuprofen, diclofenac sodium, indomethacin, colchicine, and probenocid;

enzymatic anti-inflammatory agents such as chymotrypsin and bromelain seratiopeptidase;

anti-histaminic agents such as diphenhydramine hydrochloride, chloropheniramine maleate and clemastine;

anti-allergic agents and antitussive-expectorant antiasthmatic agents such as sodium chromoglycate, codeine phosphate, and isoproterenol hydrochloride;

analgesics; and

anti-migraine compounds.

6. The particle of claim 1, wherein the pharmacologically active agent is 7-hydroxy-2-dipropyl-aminotetralin.

7. The particle of claim 2, wherein the pharmacologically active agent is a therapeutic drug used to treat glaucoma, uveitis, retinitis pigmentosa, macular degeneration, retinopathy, retinal vascular diseases, and other vascular anomalies, endophthalmitis, infectious diseases, inflammatory but non-infectious diseases, ocular ischemia syndrome, peripheral retinal degenerations, retinal degenerations, choroidal disorders and tumors, vitreous disorders, and inflammatory optic neuropathies.

8. The particle of claim 2, wherein the pharmacologically active agent is an antibiotic, an antimicrobial agent, a therapeutic monoclonal antibody, such as tetracycline hydrochloride, leucomycin, penicillin, penicillin derivatives, erythromycin, sulphathiazole and nitrofurazone;

a local anesthetic such as benzocaine;

a vasoconstrictor such as phenylephrine hydrochloride, tetrahydrozoline hydrochloride, naphazoline nitrate, oxymetazoline hydrochloride and tramazoline hydrochloride;

a cardiotonic such as digitalis and digoxin;

a vasodilator such as nitro-glycerine and papaverine hydrochloride;

an antiseptic such as chlorhexidine hydrochloride, hexylresorcinol, dequaliniumchloride and ethacridine;

an enzyme such as lysozyme chloride and dextranase;

sex hormones;

hypotensives;

sedatives;

anti-tumor agents;

steroidal anti-inflammatory agents such as hydro-cortisone, prednisone, fluticasone, prednisolone, triamcinolone, triamcinolone acetonide, dexamethasone, betamethasone, beclomethasone, and beclomethasone dipropionate;

non-steroidal anti-inflammatory agents such as acetaminophen, aspirin, aminopyrine, phenylbutazone, mefanamic acid, ibuprofen, diclofenac sodium, indomethacin, colchicine, and probenocid;

enzymatic anti-inflammatory agents such as chymotrypsin and bromelain seratiopeptidase;

anti-histaminic agents such as diphenhydramine hydrochloride, chloropheniramine maleate and clemastine;

anti-allergic agents and antitussive-expectorant antiasthmatic agents such as sodium chromoglycate, codeine phosphate, and isoproterenol hydrochloride;

analgesics; and

anti-migraine compounds.

9. The particle of claim 2, wherein the pharmacologically active agent is 7-hydroxy-2-dipropyl-aminotetralin.

10. A method for treating ocular disease, comprising delivering a particle of claim 1 to an ocular surface of the patient in need thereof, wherein the pharmacologically active agent is a therapeutic drug for treatment of ocular disease.

11. The method of claim 10, wherein the particle further comprises a surface modifying agent, such as polyethelene glycol.

12. The method of claim 10, wherein the pharmacologically active agent is a therapeutic drug used to treat glaucoma, uveitis, retinitis pigmentosa, macular degeneration, retinopathy, retinal vascular diseases, and other vascular anomalies, endophthalmitis, infectious diseases, inflammatory but non-infectious diseases, ocular ischemia syndrome, peripheral retinal degenerations, retinal degenerations, choroidal disorders and tumors, vitreous disorders, and inflammatory optic neuropathies.

13. The method of claim 10, wherein the pharmacologically active agent is an antibiotic, an antimicrobial agent, a therapeutic monoclonal antibody, such as tetracycline hydrochloride, leucomycin, penicillin, penicillin derivatives, erythromycin, sulphathiazole and nitrofurazone;

a local anesthetic such as benzocaine;

a vasoconstrictor such as phenylephrine hydrochloride, tetrahydrozoline hydrochloride, naphazoline nitrate, oxymetazoline hydrochloride and tramazoline hydrochloride;

a cardiotonic such as digitalis and digoxin;

a vasodilator such as nitro-glycerine and papaverine hydrochloride;

an antiseptic such as chlorhexidine hydrochloride, hexylresorcinol, dequaliniumchloride and ethacridine;

an enzyme such as lysozyme chloride and dextranase;

sex hormones;

hypotensives;

sedatives;

anti-tumor agents;

steroidal anti-inflammatory agents such as hydro-cortisone, prednisone, fluticasone, prednisolone, triamcinolone, triamcinolone acetonide, dexamethasone, betamethasone, beclomethasone, and beclomethasone dipropionate;

non-steroidal anti-inflammatory agents such as acetaminophen, aspirin, aminopyrine, phenylbutazone, mefanamic acid, ibuprofen, diclofenac sodium, indomethacin, colchicine, and probenocid;

enzymatic anti-inflammatory agents such as chymotrypsin and bromelain seratiopeptidase;

anti-histaminic agents such as diphenhydramine hydrochloride, chloropheniramine maleate and clemastine;

anti-allergic agents and antitussive-expectorant antiasthmatic agents such as sodium chromoglycate, codeine phosphate, and isoproterenol hydrochloride;

analgesics; and

anti-migraine compounds.

14. The method of claim 10, wherein the pharmacologically active agent is 7-hydroxy-2-dipropyl-aminotetralin.

15. A method for preparing particles suitable for the treatment of ocular disease, comprising:

(a) mixing an aqueous solution of calcium chloride with an aqueous solution of sodium citrate to form a mixture;

(b) adding an aqueous solution a sodium phosphate to the mixture to form a solution;

(c) stirring the solution until particles of the desired size and comprising calcium phosphate are obtained; and

(d) dissolving a therapeutic drug used for the treatment of ocular disease in cellobiose solution and adding this solution to the calcium phosphate particles to form particles that are at least partially coated and at least partially impregnated with the therapeutic drug.

16. The method of claim 15, wherein the stirring comprising sonicating.

17. The method of claim 15, wherein the therapeutic drug is 7-hydroxy-2-dipropyl-aminotetralin.

18. A particle comprising

(a) calcium phosphate, and

(b) a pharmacologically active agent selected from the group:

antibiotics, antimicrobial agents, therapeutic monoclonal antibodies, such as tetracycline hydrochloride, leucomycin, penicillin, penicillin derivatives, erythromycin, sulphathiazole and nitrofurazone;

local anesthetics such as benzocaine;

a vasoconstrictor such as phenylephrine hydrochloride, tetrahydrozoline hydrochloride, naphazoline nitrate, oxymetazoline hydrochloride and tramazoline hydrochloride;

cardiotonics such as digitalis and digoxin;

a vasodilators such as nitro-glycerine and papaverine hydrochloride;

antiseptics such as chlorhexidine hydrochloride, hexylresorcinol, dequaliniumchloride and ethacridine;

enzymes such as lysozyme chloride and dextranase;

sex hormones;

hypotensives;

sedatives;

anti-tumor agents;

steroidal anti-inflammatory agents such as hydro-cortisone, prednisone, fluticasone, prednisolone, triamcinolone, triamcinolone acetonide, dexamethasone, betamethasone, beclomethasone, and beclomethasone dipropionate;

non-steroidal anti-inflammatory agents such as acetaminophen, aspirin, aminopyrine, phenylbutazone, mefanamic acid, ibuprofen, diclofenac sodium, indomethacin, colchicine, and probenocid;

enzymatic anti-inflammatory agents such as chymotrypsin and bromelain seratiopeptidase;

anti-histaminic agents such as diphenhydramine hydrochloride, chloropheniramine maleate and clemastine;

anti-allergic agents and antitussive-expectorant antiasthmatic agents such as sodium chromoglycate, codeine phosphate, and isoproterenol hydrochloride;

analgesics; and

anti-migraine compounds at least partially coating the particle or impregnating the particle or both;

wherein the particle is adapted to deliver the pharmacologically active agent to an ocular surface of a patient in need thereof.